Zavegepant
💊 Brand Formulations & Prices
1 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesZaveg nasal spray is indicated for the acute treatment of migraine with or without aura in adults.
The recommended dose of Zavegepant is 10 mg given as a single spray in one nostril, as needed. The maximum dose that may be given in a 24-hour period is 10 mg (one spray). The safety of treating more than 8 migraines in a 30-day period has not been established.
Zavegepant is contraindicated in patients with a history of hypersensitivity reaction to zavegepant or any of the components of this nasal spray.
Most common adverse reactions (at least 2% of patients treated with Zaveg and greater than placebo) were taste disorders, nausea, nasal discomfort, and vomiting.
Hypersensitivity Reactions
: If a serious hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy. Hypersensitivity Reactions including facial swelling and urticaria have occurred with ZAVZPRET.
Hypertension
: New-onset or worsening of pre-existing hypertension may occur.
Raynaud's Phenomenon
: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur.
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. The relationship between pharmacodynamic activity and the mechanism by which zavegepant exerts its clinical effects is unknown. No clinically relevant differences in resting blood pressure were observed when zavegepant was concomitantly administered with sumatriptan (12 mg subcutaneous, given as two 6 mg doses separated by one hour) compared with sumatriptan alone to healthy volunteers.